Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Time to Treatment Initiation Affected by Demographics, Socioeconomics in Solid Tumors

August 2nd 2023

Delays in time to treatment initiation may be associated with demographic and socioeconomic disparities, with care coordination, clinical, and socioeconomic factors representing potential predictors of TTI, according to findings from a retrospective cohort study published in JCO Oncology Practice.

Zipalertinib Shows Antitumor Activity and a Manageable Safety Profile in EGFR Exon 20+ NSCLC

August 2nd 2023

Zipalertinib demonstrated promising efficacy as well as an acceptable safety profile in heavily pretreated patients with recurrent or metastatic non–small cell lung cancer with EGFR exon 20 insertions.

Small Cell Lung Cancer: What is the Role of Biomarker Testing?

July 31st 2023

Shared insight on the early but evolving role of biomarker testing in patients diagnosed with extensive- or limited-stage small cell lung cancer.

Current Strategies in Diagnosis and Classification of Small Cell Lung Cancer

July 31st 2023

Expert oncologists Laurent Greiller, MD, and Christian Grohé, MD, make introductions and review the current paradigm for small cell lung cancer diagnosis and classification.

Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy

July 31st 2023

A panel of expert oncologists present the case of a 78-year-old woman who is treated with lurbinectedin following disease progress on first-line carboplatin, etoposide, and atezolizumab.

Evolving Treatment Strategies for SCLC in the Second-Line Setting and Beyond

July 31st 2023

Panel experts discuss evolving treatment options for small-cell lung cancer in the second-line setting and beyond.

Several Research Avenues Are Available for Improving Response to Immunotherapy in Advanced NSCLC

July 29th 2023

Tony S.K. Mok, MD, BMSc, FRCPC, FASCO, highlights novel partners and potential new approaches for immunotherapy-based regimens for the treatment of patients with non–small cell lung cancer.

ADCs Offer Exciting Potential in Lung Cancer

July 29th 2023

Antibody-drug conjugates represent one of the most exciting areas of ongoing development for the treatment of patients with non–small cell lung cancer and small cell lung cancer.

Dr Tsuboi on Updated Survival Results of the ADAURA Trial in Resectable NSCLC

July 29th 2023

Masahiro Tsuboi, MD, discusses the updated survival results of the phase 3 ADAURA trial in resectable EGFR-mutant non–small cell lung cancer.

Dr Bazhenova on Potential Combination Strategies With KRAS G12C Inhibitors in Advanced NSCLC

July 29th 2023

Lyudmila A. Bazhenova, MD, discusses potential combination strategies with KRAS G12C inhibitors in advanced non–small cell lung cancer.

Up-front Testing Is Imperative for Treatment Decisions in RET+ NSCLC

July 29th 2023

Deborah B. Doroshow, MD, PhD, discusses the efficacy and toxicity profiles of pralsetinib and selpercatinib and how they influence treatment selection for patients with RET fusion–positive non–small cell lung cancer, and provides insight on several areas of ongoing or potential research in lung cancer.

Dr Husain on Developments in ALK+ NSCLC

July 29th 2023

Hatim Husain, MD, discusses developments in ALK-positive non–small cell lung cancer.

Dr Santos on Testing and Treatment in NRG1 Fusion–Positive NSCLC

July 29th 2023

Edgardo Santos, MD, FACP, FCCP, discusses testing and treatment in NRG1 fusion–positive non–small cell lung cancer.

Lung Cancer Trials Require Modified Eligibility Criteria to Better Reflect Real-World Population

July 28th 2023

Edward S. Kim, MD, MBA, discusses necessary changes that would make cancer research more accessible to patients in community settings, multidisciplinary efforts that should take place at every step of the trial design and implementation process, and how future clinical trials should be intentional about the patient demographics.

Tackling Resistance Mechanisms Is the Next Step in Immunotherapy Development for NSCLC

July 28th 2023

Immunotherapy administered alone or in combination with chemotherapy has become the standard of care across advanced non–small cell lung cancer in several settings, with continued effort devoted to further enhancing and improving upon these treatments.

Consolidation Immunotherapy in Unresectable Early NSCLC: Novel Approaches

July 28th 2023

Sandip Patel, MD, shares his expert perspectives on novel combination consolidation immunotherapy regimens that are under evaluation in unresectable early-stage NSCLC.

Perioperative Nivolumab Plus Chemo Improves pCR, Survival in Stage III NSCLC

July 28th 2023

Neoadjuvant treatment with nivolumab plus platinum-based chemotherapy followed by adjuvant nivolumab increased pathological complete response rates and prolonged survival compared with neoadjuvant chemotherapy alone in patients with resectable stage IIIA/B non–small cell lung cancer.

Dr Peters on Understanding Mechanisms of Resistance to Immunotherapy in NSCLC

July 27th 2023

Solange Peters, MD, PhD, discusses current understandings of mechanisms of resistance to immunotherapy in non–small cell lung cancer.

Perioperative Immunotherapy Improves EFS, But Clouds Optimal Sequencing in Early NSCLC

July 27th 2023

Positive event-free survival data from the phase 3 AEGEAN, NEOTORCH, and KEYNOTE-671 trials add further evidence to the benefit of perioperative immunotherapy in early-stage non–small cell lung cancer but have yet to show clear biomarkers of response beyond PD-L1.

Dr Roof on Disparities in Lung Cancer Mortality Rates in the United States

July 27th 2023

Logan Roof, MD, discusses findings from a study investigating trends in lung cancer mortality across different sociodemographic populations and locations in the United States between 1999 and 2020.